Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies

W. D. Hooper, A. R. King, M. Patterson, R. G. Dickinson, M. J. Eadie

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A comparative bioavailability study of carbamazepine (CBZ) in tablets and a syrup preparation was carried out in six volunteers, using a crossover design. Plasma and saliva samples were collected at appropriate times, and the plasma specimens were analyzed by high performance liquid chromatography for concentrations of CBZ and its epoxide metabolite (CBZ-EP). Analysis of the data showed that the preparations were equally bioavailable, although absorption was faster from the syrup and gave higher maximum plasma levels of CBZ. In other aspects the preparations were pharmacokinetically equivalent. Analysis of simultaneous plasma CBZ and CBZ-EP concentration-time data by iterative curve fitting to a one-compartment linear model permitted the calculation of elimination kinetic parameters of the CBZ-EP; the mean elimination half-life was 6.9 ± 2.7 h. Failure of the salivary CBZ concentrations soon after drug intake to correlate with simultaneous plasma CBZ levels rendered the salivary data useless for bioavailability comparison, but prompted a further study of salivary CBZ levels.

Original languageEnglish (US)
Pages (from-to)36-40
Number of pages5
JournalTherapeutic Drug Monitoring
Volume7
Issue number1
StatePublished - 1985
Externally publishedYes

Fingerprint

Pharmacokinetics
Carbamazepine
Biological Availability
Plasmas
carbamazepine epoxide
High performance liquid chromatography
Curve fitting
Metabolites
Saliva
Kinetic parameters
Cross-Over Studies
Tablets
Half-Life
Volunteers
Linear Models
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Hooper, W. D., King, A. R., Patterson, M., Dickinson, R. G., & Eadie, M. J. (1985). Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies. Therapeutic Drug Monitoring, 7(1), 36-40.

Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies. / Hooper, W. D.; King, A. R.; Patterson, M.; Dickinson, R. G.; Eadie, M. J.

In: Therapeutic Drug Monitoring, Vol. 7, No. 1, 1985, p. 36-40.

Research output: Contribution to journalArticle

Hooper, WD, King, AR, Patterson, M, Dickinson, RG & Eadie, MJ 1985, 'Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies', Therapeutic Drug Monitoring, vol. 7, no. 1, pp. 36-40.
Hooper, W. D. ; King, A. R. ; Patterson, M. ; Dickinson, R. G. ; Eadie, M. J. / Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies. In: Therapeutic Drug Monitoring. 1985 ; Vol. 7, No. 1. pp. 36-40.
@article{03e13c198f3142858a7dae3ae6e1e50e,
title = "Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies",
abstract = "A comparative bioavailability study of carbamazepine (CBZ) in tablets and a syrup preparation was carried out in six volunteers, using a crossover design. Plasma and saliva samples were collected at appropriate times, and the plasma specimens were analyzed by high performance liquid chromatography for concentrations of CBZ and its epoxide metabolite (CBZ-EP). Analysis of the data showed that the preparations were equally bioavailable, although absorption was faster from the syrup and gave higher maximum plasma levels of CBZ. In other aspects the preparations were pharmacokinetically equivalent. Analysis of simultaneous plasma CBZ and CBZ-EP concentration-time data by iterative curve fitting to a one-compartment linear model permitted the calculation of elimination kinetic parameters of the CBZ-EP; the mean elimination half-life was 6.9 ± 2.7 h. Failure of the salivary CBZ concentrations soon after drug intake to correlate with simultaneous plasma CBZ levels rendered the salivary data useless for bioavailability comparison, but prompted a further study of salivary CBZ levels.",
author = "Hooper, {W. D.} and King, {A. R.} and M. Patterson and Dickinson, {R. G.} and Eadie, {M. J.}",
year = "1985",
language = "English (US)",
volume = "7",
pages = "36--40",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies

AU - Hooper, W. D.

AU - King, A. R.

AU - Patterson, M.

AU - Dickinson, R. G.

AU - Eadie, M. J.

PY - 1985

Y1 - 1985

N2 - A comparative bioavailability study of carbamazepine (CBZ) in tablets and a syrup preparation was carried out in six volunteers, using a crossover design. Plasma and saliva samples were collected at appropriate times, and the plasma specimens were analyzed by high performance liquid chromatography for concentrations of CBZ and its epoxide metabolite (CBZ-EP). Analysis of the data showed that the preparations were equally bioavailable, although absorption was faster from the syrup and gave higher maximum plasma levels of CBZ. In other aspects the preparations were pharmacokinetically equivalent. Analysis of simultaneous plasma CBZ and CBZ-EP concentration-time data by iterative curve fitting to a one-compartment linear model permitted the calculation of elimination kinetic parameters of the CBZ-EP; the mean elimination half-life was 6.9 ± 2.7 h. Failure of the salivary CBZ concentrations soon after drug intake to correlate with simultaneous plasma CBZ levels rendered the salivary data useless for bioavailability comparison, but prompted a further study of salivary CBZ levels.

AB - A comparative bioavailability study of carbamazepine (CBZ) in tablets and a syrup preparation was carried out in six volunteers, using a crossover design. Plasma and saliva samples were collected at appropriate times, and the plasma specimens were analyzed by high performance liquid chromatography for concentrations of CBZ and its epoxide metabolite (CBZ-EP). Analysis of the data showed that the preparations were equally bioavailable, although absorption was faster from the syrup and gave higher maximum plasma levels of CBZ. In other aspects the preparations were pharmacokinetically equivalent. Analysis of simultaneous plasma CBZ and CBZ-EP concentration-time data by iterative curve fitting to a one-compartment linear model permitted the calculation of elimination kinetic parameters of the CBZ-EP; the mean elimination half-life was 6.9 ± 2.7 h. Failure of the salivary CBZ concentrations soon after drug intake to correlate with simultaneous plasma CBZ levels rendered the salivary data useless for bioavailability comparison, but prompted a further study of salivary CBZ levels.

UR - http://www.scopus.com/inward/record.url?scp=0021912592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021912592&partnerID=8YFLogxK

M3 - Article

C2 - 3992620

AN - SCOPUS:0021912592

VL - 7

SP - 36

EP - 40

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -